BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).

Latest News

Upcoming Events

US clinical trial BCT-001-US - December 09, 2016

BCT-001-US Phase II Study Topline Results - July 18, 2016

Poster Presentation from 67th American Academy of Neurology - April 21, 2015

Investor Presentation - March 2015